Biomarin Pharmaceutical Stock Price on September 30, 2023
| BMRN Stock | USD 82.44 1.36 1.62% |
Below is the normalized historical share price chart for Biomarin Pharmaceutical extending back to July 23, 1999. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Biomarin Pharmaceutical stands at 82.44, as last reported on the 3rd of May, with the highest price reaching 84.80 and the lowest price hitting 82.32 during the day.
If you're considering investing in Biomarin Stock, it is important to understand the factors that can impact its price. Biomarin Pharmaceutical secures Sharpe Ratio (or Efficiency) of -0.0312, which signifies that the company had a -0.0312% return per unit of risk over the last 3 months. Biomarin Pharmaceutical exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Biomarin Pharmaceutical's Standard Deviation of 1.77, risk adjusted performance of (0.02), and Mean Deviation of 1.15 to double-check the risk estimate we provide.
At this time, Biomarin Pharmaceutical's Total Stockholder Equity is very stable compared to the past year. As of the 3rd of May 2024, Liabilities And Stockholders Equity is likely to grow to about 7.2 B, while Common Stock Shares Outstanding is likely to drop about 127.6 M. . At this time, Biomarin Pharmaceutical's Price Cash Flow Ratio is very stable compared to the past year. As of the 3rd of May 2024, Price Fair Value is likely to grow to 3.99, while Price To Sales Ratio is likely to drop 7.11. Biomarin Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 23rd of July 1999 | 200 Day MA 88.9877 | 50 Day MA 87.1146 | Beta 0.32 |
Biomarin |
Sharpe Ratio = -0.0312
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMRN |
Estimated Market Risk
| 1.8 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biomarin Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomarin Pharmaceutical by adding Biomarin Pharmaceutical to a well-diversified portfolio.
Price Book 3.5356 | Enterprise Value Ebitda 56.6008 | Price Sales 7.2342 | Shares Float 188.4 M | Wall Street Target Price 110.1 |
Biomarin Pharmaceutical Valuation on September 30, 2023
It is possible to determine the worth of Biomarin Pharmaceutical on a given historical date. On September 30, 2023 Biomarin was worth 89.57 at the beginning of the trading date compared to the closed value of 88.48. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Biomarin Pharmaceutical stock. Still, in general, we apply an absolute valuation method to find Biomarin Pharmaceutical's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biomarin Pharmaceutical where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Biomarin Pharmaceutical's related companies.
| Open | High | Low | Close | Volume | |
| 89.54 | 90.15 | 88.43 | 89.25 | 1,357,856 | |
09/29/2023 | 89.57 | 89.92 | 88.34 | 88.48 | 1,510,042 |
| 88.35 | 88.35 | 85.86 | 87.08 | 1,689,766 |
| Backtest Biomarin Pharmaceutical | | | Biomarin Pharmaceutical History | | | Biomarin Pharmaceutical Valuation | Previous | Next |
Biomarin Pharmaceutical Trading Date Momentum on September 30, 2023
| On October 02 2023 Biomarin Pharmaceutical was traded for 87.08 at the closing time. The top price for the day was 88.35 and the lowest listed price was 85.86 . The trading volume for the day was 1.7 M. The trading history from October 2, 2023 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 1.58% . The overall trading delta against the current closing price is 1.84% . |
Biomarin Pharmaceutical Fundamentals Correlations and Trends
By evaluating Biomarin Pharmaceutical's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Biomarin financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Biomarin Pharmaceutical Stock history
Biomarin Pharmaceutical investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Biomarin is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Biomarin Pharmaceutical will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Biomarin Pharmaceutical stock prices may prove useful in developing a viable investing in Biomarin Pharmaceutical
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 191.6 M | 127.6 M | |
| Net Income Applicable To Common Shares | 162.8 M | 170.9 M |
Biomarin Pharmaceutical Quarterly Net Working Capital |
|
Biomarin Pharmaceutical Stock Technical Analysis
Biomarin Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Biomarin Pharmaceutical Period Price Range
Low | September 29, 2023
| High |
89.57 | 88.48 |
Biomarin Pharmaceutical May 3, 2024 Market Strength
Market strength indicators help investors to evaluate how Biomarin Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Biomarin Pharmaceutical shares will generate the highest return on investment. By undertsting and applying Biomarin Pharmaceutical stock market strength indicators, traders can identify Biomarin Pharmaceutical entry and exit signals to maximize returns
| Accumulation Distribution | 26533.21 | |||
| Daily Balance Of Power | (0.69) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 89.13 | |||
| Day Typical Price | 88.91 | |||
| Price Action Indicator | (1.19) | |||
| Period Momentum Indicator | (6.04) | |||
| Relative Strength Index | 41.7 |
Biomarin Pharmaceutical Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Biomarin Pharmaceutical's price direction in advance. Along with the technical and fundamental analysis of Biomarin Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Biomarin to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.13) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.722 | Earnings Share 1.06 | Revenue Per Share 13.12 | Quarterly Revenue Growth 0.088 | Return On Assets 0.0177 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.